Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
What’s Behind Cannabis Stock HERB? (click to learn more) CSE: ALEN.U — AI Meets Digital Health (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Price History  |  Ratios  |  Insiders

Stock Quote Today & Recent News AxoGen Inc AXGN

Healthcare Medical Devices
Axogen, Inc., together with its subsidiaries, develops and commercializes technologies for peripheral nerve regeneration and repair worldwide. The company’s products include Avance Nerve Graft, a biologically active off-the-shelf processed human nerve allograft for bridging severed peripheral nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a... see more
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >

Current News (NDAQ:AXGN)

Axogen, Inc. to Report Fourth Quarter and Full Year 2025 Financial Results on February 24, 2026

GlobeNewswire 2 hours ago

Axogen Announces Pricing of Upsized $124 Million Public Offering of Common Stock

GlobeNewswire January 21, 2026

Axogen Announces Proposed Public Offering of Common Stock

GlobeNewswire January 21, 2026

Axogen, Inc. Reports Preliminary Unaudited Revenue for Fourth Quarter and Full-Year 2025

GlobeNewswire January 12, 2026

Axogen, Inc. to Participate in the J.P. Morgan 2026 Healthcare Conference

GlobeNewswire December 17, 2025

Axogen Announces FDA Approval of Biologics License Application for AVANCE® (acellular nerve allograft-arwx)

GlobeNewswire December 3, 2025

Axogen, Inc. to Participate in Multiple Upcoming Investor Conferences

GlobeNewswire November 4, 2025

Axogen, Inc. Reports Third Quarter 2025 Financial Results

GlobeNewswire October 29, 2025

Bronstein, Gewirtz & Grossman, LLC Is Investigating Axogen, Inc. (AXGN) And Encourages Shareholders to Connect

ACCESS Newswire October 19, 2025
View More News ››

Opinion & Analysis (NDAQ:AXGN)

No current opinion is available.
View More Opinion ››

Bullboard Posts (NDAQ:AXGN)

AXOGEN: REPAIRING LIVES OF PATIENTS WITH PERIPHERAL NERVE IN

$AXGN Excited to share an article about  Axogen, Inc. (NASDAQ: AXGN), a leader in developing and marketing...
AviseAnalytics - January 24, 2024

AxoGen Inc. (AXGN) Poised For Strong Growth In Reg

Nerve damaging injuries and surgeries can lead to a life of despair for the patient, leaving them with limited, or no, ability to move...
MissionIR - April 3, 2012
View more Bullboard ››

Vanstar Mining Resources Inc.

Vanstar Mining Resources Inc.

Vanstar Mining’s Nelligan gold project joint venture with IAMGOLD (25% VSR/75% IMG), located 60 kilometres SW of Chibougamau, ...
View More »

Podcasts